Kiniksa Pharmaceuticals Files 8-K

Ticker: KNSA · Form: 8-K · Filed: 2024-04-02T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, filing, regulation-fd

TL;DR

Kiniksa dropped an 8-K, check it for updates.

AI Summary

Kiniksa Pharmaceuticals, Ltd. filed an 8-K on April 2, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure or exhibits in the provided text.

Why It Matters

This filing indicates an official update from Kiniksa Pharmaceuticals to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural update and does not contain specific negative or positive financial news.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is April 2, 2024.

Where is Kiniksa Pharmaceuticals, Ltd. incorporated?

Kiniksa Pharmaceuticals, Ltd. is incorporated in Bermuda.

What is the Commission File Number for Kiniksa Pharmaceuticals, Ltd.?

The Commission File Number for Kiniksa Pharmaceuticals, Ltd. is 001-730430.

What is the business address and phone number of Kiniksa Pharmaceuticals, Ltd.?

The business address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda, and the telephone number is (808) 451-3453.

Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-04-02 07:32:54

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On April 2, 2024, Kiniksa Pharmaceuticals, Ltd. (the "Company") issued a press release (the "Press Release") announcing, among other things, (i) its plans to initiate a Phase 2b clinical trial of abiprubart in Sjogren's Disease, including clinical trial design for such trial, (ii) topline data from Cohort 4 of its Phase 2 clinical trial of abiprubart in rheumatoid arthritis and (iii) that it expected to remain cash flow positive on an annual basis within its current operating plan. In connection with such announcement, the Company posted an investor presentation (the "Investor Presentation") containing information related to the above, among other things, to its website at investors.kiniksa.com. A copy of the Press Release and the Investor Presentation are furnished with this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Kiniksa Pharmaceuticals, Ltd., dated April 2, 2024 99.2 Kiniksa Pharmaceuticals, Ltd. Investor Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: April 2, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary

View on Read The Filing